Across 5 research centers, investigators evaluated the impact of eculizumab on thymoma-associated myasthenia gravis, a severe ...

Medications for myasthenia gravis (MG) can include cholinesterase inhibitors, corticosteroids, immunosuppressants, monoclonal antibodies, and antibody fragment medications. While myasthenia gravis ...

The application is supported by data from the randomized, double-blind, placebo-controlled phase 3 Vivacity-MG3 study.

The FDA has granted priority review to a Biologics License Application for nipocalimab to treat individuals with generalized ...

1 "We welcome the FDA's decision to grant Priority Review for the treatment of generalized myasthenia gravis, which underscores the need for additional treatment options in a broad population of ...

Priority Review was based on results from the Phase III Vivacity-MG3 study of nipocalimab in patients with generalized myasthenia gravis. The FDA has granted Priority Review to a Biologics License ...

PR Newswire NEW YORK, Jan. 9, 2025 NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The global premature ejaculation treatment market size is estimated to grow by USD 1.53 billion from 2025 to 2029, according ...

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis. The New Brunswick ...